An Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Sequence, Crossover, Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of TR-701 (Torezolid Phosphate) in Normal Healthy Adults

Trial Profile

An Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Sequence, Crossover, Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of TR-701 (Torezolid Phosphate) in Normal Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 04 May 2016

At a glance

  • Drugs Tedizolid (Primary)
  • Indications Gram-positive infections; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors Trius Therapeutics
  • Most Recent Events

    • 07 Aug 2013 Results published in Pharmacotherapy.
    • 07 Sep 2010 Results will be presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting according to a Truis Therapeutics media release.
    • 20 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top